- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Board Meeting, 12-02-2026: Outcome of Board Meeting
12-02-2026 | 09:19 pm
12-02-2026 | 09:19 pm
Lupin's board approved consolidated Q3 & nine-month results. Q3 PAT hit ₹1,170.5 Cr on ₹7,167.5 Cr revenue. Strategic moves included settling legal disputes, gaining an arbitration award, and acquiring Renascience Pharma.
No comments yet. Be the first to comment!